Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap
- 28 September 2010
- journal article
- review article
- Published by Elsevier BV in The Lancet Neurology
- Vol. 9 (11), 1106-1117
- https://doi.org/10.1016/s1474-4422(10)70218-0
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- MK-801 inhibits l-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonismNeuropharmacology, 2010
- Effects of a Dopamine Agonist on the Pharmacodynamics of Levodopa in Parkinson DiseaseArchives of Neurology, 2010
- Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned ratsNeuroscience, 2009
- Striatal Overexpression of ΔJunD Resets L-DOPA-Induced Dyskinesia in a Primate Model of Parkinson DiseaseBiological Psychiatry, 2009
- Dysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of motor side-effects induced by anti-parkinsonian therapyProceedings of the National Academy of Sciences of the United States of America, 2009
- Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2Neurochemistry International, 2008
- Effects of a NR2B selective NMDA glutamate antagonist, CP‐101,606, on dyskinesia and parkinsonismMovement Disorders, 2008
- Priming for l-dopa-induced dyskinesia in Parkinson’s disease: A feature inherent to the treatment or the disease?Progress in Neurobiology, 2008
- Placebo influences on dyskinesia in Parkinson's diseaseMovement Disorders, 2008
- Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: Role of CB1 and TRPV1 receptorsExperimental Neurology, 2007